Search

Your search keyword '"B. Vire"' showing total 38 results

Search Constraints

Start Over You searched for: Author "B. Vire" Remove constraint Author: "B. Vire"
38 results on '"B. Vire"'

Search Results

1. Demonstration of neutron identification in neutrino interactions in the MicroBooNE liquid argon time projection chamber

2. Charged-current non-standard neutrino interactions at Daya Bay

3. RNA editing blood biomarkers for predicting mood alterations in HCV patients

4. Performance of a Modular Ton-Scale Pixel-Readout Liquid Argon Time Projection Chamber

5. Reconstruction of interactions in the ProtoDUNE-SP detector with Pandora

6. ICARUS at the Fermilab Short-Baseline Neutrino program: initial operation

7. Separation of track- and shower-like energy deposits in ProtoDUNE-SP using a convolutional neural network

8. Predicting suicidal behavior by an accurate monitoring of RNA editing biomarkers in blood samples

9. Scintillation light detection in the 6-m drift-length ProtoDUNE Dual Phase liquid argon TPC

11. Novel approach for evaluating detector-related uncertainties in a LArTPC using MicroBooNE data

12. Blood epitranscriptomic biomarkers to predict suicidal behavior

13. Calorimetric classification of track-like signatures in liquid argon TPCs using MicroBooNE data

14. Supernova neutrino burst detection with the deep underground neutrino experiment

15. Prospects for beyond the Standard Model physics searches at the Deep Underground Neutrino Experiment

16. Long-baseline neutrino oscillation physics potential of the DUNE experiment

17. Rejecting cosmic background for exclusive charged current quasi elastic neutrino interaction studies with Liquid Argon TPCs; a case study with the MicroBooNE detector

18. Comparison of $${\varvec{\nu }}_{\varvec{\mu }}-$$ νμ- Ar multiplicity distributions observed by MicroBooNE to GENIE model predictions

19. The Pandora multi-algorithm approach to automated pattern recognition of cosmic-ray muon and neutrino events in the MicroBooNE detector

20. Deep Underground Neutrino Experiment (DUNE) Near Detector Conceptual Design Report

21. Plasma hPG 80 (Circulating Progastrin) as a Novel Prognostic Biomarker for early-stage breast cancer in a breast cancer cohort.

22. hPG 80 (circulating progastrin) as a blood biomarker for high-grade glial tumors: A pilot study.

23. [hPG 80 and cancer: A new blood biomarker in development for patient monitoring].

24. hPG 80 (Circulating Progastrin), a Novel Blood-Based Biomarker for Detection of Poorly Differentiated Neuroendocrine Carcinoma and Well Differentiated Neuroendocrine Tumors.

25. A novel method to detect hPG 80 (human circulating progastrin) in the blood.

26. Prognostic Value of Plasma hPG 80 (Circulating Progastrin) in Metastatic Renal Cell Carcinoma.

27. The oncogenic and druggable hPG80 (Progastrin) is overexpressed in multiple cancers and detected in the blood of patients.

28. RNA editing blood biomarkers for predicting mood alterations in HCV patients.

29. Targeting the Wnt Pathway and Cancer Stem Cells with Anti-progastrin Humanized Antibodies as a Potential Treatment for K-RAS-Mutated Colorectal Cancer.

30. Harnessing the fcμ receptor for potent and selective cytotoxic therapy of chronic lymphocytic leukemia.

31. Rapid clearance of rituximab may contribute to the continued high incidence of autoimmune hematologic complications of chemoimmunotherapy for chronic lymphocytic leukemia.

32. TOSO, the Fcmicro receptor, is highly expressed on chronic lymphocytic leukemia B cells, internalizes upon IgM binding, shuttles to the lysosome, and is downregulated in response to TLR activation.

33. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

34. Rituximab: therapeutic benefit! Vitamin R?

35. Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia.

36. Anti-leukemia activity of MS-275 histone deacetylase inhibitor implicates 4-1BBL/4-1BB immunomodulatory functions.

37. Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia.

38. Active transcription of the human FASL/CD95L/TNFSF6 promoter region in T lymphocytes involves chromatin remodeling: role of DNA methylation and protein acetylation suggest distinct mechanisms of transcriptional repression.

Catalog

Books, media, physical & digital resources